Get regular updates to your inbox.
Men with ANCA-associated vasculitis (AAV) have a 1.54 times higher risk of dying within one year than female patients, a new study finds. According to authors, “this [finding] may provide a reliable predictor for clinicians to judge the prognosis and select active treatment for patients with AAV.” The report,…
Read more
The number of ANCA-associated vasculitis (AAV) cases in Spain more than doubled between 2019 and 2021 following mass-scale vaccination against SARS-CoV-2, the virus that causes COVID-19, a new study found, suggesting the vaccine as a possible trigger. Researchers suspect the development of ANCA antibodies and AAV could be among…
After approximately $3.7 billion in acquisitions, Amgen will own the rights to Tavneos (avacopan), an approved oral therapy developed by ChemoCentryx to treat ANCA-associated vasculitis (AAV). Amgen is acquiring ChemoCentryx in a cash deal, expected to be completed by year’s end, the companies announced. “The acquisition of ChemoCentryx represents a…
Columnist Allison Ross speaks from experience when she advises readers on how to get over a depressive episode.
Click the link below to find all the latest news related to ANCA vasculitis.
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
